Takeda/Shire deal is moving one step ahead
Our expert's opinion
"After approval of the US, China and Brazil, Japanese authorities have approved the Takeda’s deal on Shire for $62 billion. Next step is to get the EU approval, where a decision is due for the 6th of November. If this happens, the merged company will be part of the top 10 global pharma companies."
- Jérome Goffin, Senior Associate
Takeda gets Japanese approval for $62 billion Shire purchase
Takeda Pharmaceutical Co Ltd (4502.T) said on Thursday Japan’s Fair Trade Commission had approved its $62 billion acquisition of Shire Plc (SHP.L), bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.
The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States, Brazil and China.
“Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,” Takeda CEO Christophe Weber said in a statement.
Takeda is also waiting for a nod from EU antitrust regulators. They are expected to make a decision by Nov. 6 but can open a four-month long investigation if they have serious concerns.
Other insights in Pharmaceutical Affairs
Read our insight
Working as a pharma professional at Strand: what is it like?